# Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

> **NCT03402386** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 42 (actual)

## Conditions studied

- Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** MT-6548

## Key facts

- **NCT ID:** NCT03402386
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-03
- **Primary completion:** 2018-11-22
- **Final completion:** 2018-12-20
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402386, "Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03402386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*